MCID: OVR044
MIFTS: 35

Ovarian Carcinosarcoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Carcinosarcoma

MalaCards integrated aliases for Ovarian Carcinosarcoma:

Name: Ovarian Carcinosarcoma 12 54 60 15 17
Ovarian Malignant Mixed Epithelial Mesenchymal Tumor 54 60
Malignant Mixed Müllerian Tumor of the Ovary 54 60
Ovarian Malignant Mixed Müllerian Tumor 54 60
Mmmt of the Ovary 54 60
Malignant Mixed Mullerian Tumor of the Ovary 54
Ovarian Malignant Mesodermal Mixed Tumor 12
Ovarian Malignant Mixed Mullerian Tumor 12
Carcinosarcoma of Ovary 74
Ovarian Mmmt 12

Characteristics:

Orphanet epidemiological data:

60

Classifications:



External Ids:

Disease Ontology 12 DOID:6170
NCIt 51 C9192
ICD10 via Orphanet 35 C56
UMLS via Orphanet 75 C0392998
Orphanet 60 ORPHA213512
UMLS 74 C0392998

Summaries for Ovarian Carcinosarcoma

NIH Rare Diseases : 54 Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of ovarian carcinosarcoma is not yet understood. Treatment usually consists of surgery to remove the tumor and chemotherapy. The chance of recovery and long-term survival (prognosis) is poor, with a reported 5-year survival rate of about 28%.

MalaCards based summary : Ovarian Carcinosarcoma, also known as ovarian malignant mixed epithelial mesenchymal tumor, is related to carcinosarcoma and breast cancer. An important gene associated with Ovarian Carcinosarcoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2). The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, brain and endothelial.

Disease Ontology : 12 A malignant ovarian surface epithelial-stromal neoplasm that is a mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Related Diseases for Ovarian Carcinosarcoma

Diseases related to Ovarian Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 49)
# Related Disease Score Top Affiliating Genes
1 carcinosarcoma 10.7
2 breast cancer 10.1
3 inguinal hernia 10.1
4 bilateral breast cancer 10.1
5 uterine corpus serous adenocarcinoma 10.1 ERBB2 TUBB3
6 uterine corpus cancer 10.1 ERBB2 TUBB3
7 adenocarcinoma 10.1
8 papillary adenocarcinoma 10.1
9 teratoma 10.0
10 stomach disease 10.0 ERBB2 TUBB3
11 paralytic squint 10.0 FUT2 TUBB3
12 female reproductive system disease 10.0 ERBB2 TUBB3
13 reproductive system disease 10.0 ERBB2 TUBB3
14 gonadal disease 10.0 ERBB2 TUBB3
15 breast neuroendocrine neoplasm 10.0 ERBB2 SYP
16 gastrointestinal system cancer 10.0 ERBB2 TUBB3
17 mixed cell type cancer 9.9 ERBB2 SYP
18 granulosa cell tumor of the ovary 9.9 ERBB2 SYP
19 tubular adenocarcinoma 9.9 ERBB2 SYP
20 sweat gland cancer 9.9 ERBB2 SYP
21 myeloma, multiple 9.9
22 tubulin, beta 9.9
23 angiosarcoma 9.9
24 squamous cell carcinoma 9.9
25 melanoma 9.9
26 cystic teratoma 9.9
27 cystadenocarcinoma 9.9
28 serous cystadenocarcinoma 9.9
29 rhabdomyosarcoma 9.9
30 liposarcoma 9.9
31 mature teratoma 9.9
32 pleomorphic liposarcoma 9.9
33 cerebellar degeneration 9.9
34 paraneoplastic cerebellar degeneration 9.9
35 respiratory system disease 9.9 CD274 TUBB3
36 olfactory nerve neoplasm 9.9 SYP TUBB3
37 pineal gland cancer 9.9 SYP TUBB3
38 pineocytoma 9.9 SYP TUBB3
39 respiratory system cancer 9.9 CD274 ERBB2 TUBB3
40 cranial nerve malignant neoplasm 9.9 SYP TUBB3
41 pineal parenchymal tumor of intermediate differentiation 9.9 SYP TUBB3
42 merkel cell carcinoma 9.8 CD274 SYP
43 adult medulloblastoma 9.8 SYP TUBB3
44 thymus cancer 9.8 CD274 SYP
45 central nervous system cancer 9.8 SYP TUBB3
46 nervous system cancer 9.8 SYP TUBB3
47 endocrine gland cancer 9.7 ERBB2 SYP TUBB3
48 nervous system disease 9.5 SYP TUBB3
49 lung cancer 9.1 CD274 ERBB2 SYP TUBB3

Graphical network of the top 20 diseases related to Ovarian Carcinosarcoma:



Diseases related to Ovarian Carcinosarcoma

Symptoms & Phenotypes for Ovarian Carcinosarcoma

Drugs & Therapeutics for Ovarian Carcinosarcoma

Drugs for Ovarian Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
4
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
5
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
8
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
9
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
10
Histamine Approved, Investigational Phase 3 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Doxil Approved June 1999 Phase 2, Phase 3,Phase 1 31703
13 Antimitotic Agents Phase 3,Phase 2,Phase 1
14 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
16 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
17 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2
20 Alkylating Agents Phase 3,Phase 2
21
Isophosphamide mustard Phase 3 0
22 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
23 Histamine Antagonists Phase 3
24 Neurotransmitter Agents Phase 3
25 Gastrointestinal Agents Phase 3
26 Serotonin Agents Phase 3
27 Serotonin Antagonists Phase 3
28 Anti-Allergic Agents Phase 3
29 Antipruritics Phase 3
30 Dermatologic Agents Phase 3
31 Histamine H1 Antagonists Phase 3
32
Histamine Phosphate Phase 3 51-74-1 65513
33
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
34
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
35
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
36
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
37
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
38
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751
39
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
40
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
41
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
42
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
43
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
44
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
45
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
46
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
47
Entinostat Investigational Phase 1, Phase 2 209783-80-2
48 Antimetabolites Phase 2
49 Immunologic Factors Phase 2,Phase 1
50 Antiviral Agents Phase 2

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Not yet recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
6 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
7 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
8 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
9 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
10 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
11 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
12 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
13 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
14 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
15 LN-145 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine Phosphate
16 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
17 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
18 Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Not yet recruiting NCT03924245 Phase 1, Phase 2 Entinostat;Olaparib
19 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
20 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
21 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
22 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
23 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
24 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
25 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
26 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors Recruiting NCT03641287 Not Applicable
27 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Terminated NCT00904514

Search NIH Clinical Center for Ovarian Carcinosarcoma

Genetic Tests for Ovarian Carcinosarcoma

Anatomical Context for Ovarian Carcinosarcoma

MalaCards organs/tissues related to Ovarian Carcinosarcoma:

42
Ovary, Brain, Endothelial, Pineal, Lymph Node, Small Intestine, Thymus

Publications for Ovarian Carcinosarcoma

Articles related to Ovarian Carcinosarcoma:

(show all 48)
# Title Authors Year
1
Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube. ( 30913944 )
2019
2
A rare case of ovarian carcinosarcoma with squamous cell carcinoma. ( 30947745 )
2019
3
Ovarian carcinosarcoma: Current developments and future perspectives. ( 30771873 )
2019
4
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. ( 29426293 )
2018
5
Usefulness of ascites cytology for the evaluation of chemotherapy response in ovarian carcinosarcoma. ( 29488261 )
2018
6
Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma. ( 30022854 )
2018
7
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. ( 30147940 )
2018
8
Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. ( 30345126 )
2018
9
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. ( 27958685 )
2017
10
Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. ( 28125702 )
2017
11
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. ( 28679774 )
2017
12
Paraneoplastic cerebellar degeneration secondary to ovarian carcinosarcoma: a cerebellar conundrum. ( 28790096 )
2017
13
Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma. ( 28791266 )
2017
14
Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. ( 27107722 )
2016
15
Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma. ( 27807494 )
2016
16
Mature Teratoma Associated with Bilateral Ovarian Carcinosarcoma - Accidental Association or Etiopathogenetic Determinism? - Case Report. ( 27819640 )
2016
17
Ovarian carcinosarcoma: a case report, diagnosis, treatment and literature review. ( 27418786 )
2015
18
Presence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid. ( 25802693 )
2015
19
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. ( 25962155 )
2015
20
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. ( 26474755 )
2015
21
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. ( 25341582 )
2014
22
Ovarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor. ( 26052208 )
2014
23
Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma. ( 24587930 )
2014
24
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. ( 24631447 )
2014
25
A rare case of ovarian carcinosarcoma with neuroendocrine differentiation. ( 24971408 )
2014
26
Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. ( 23450567 )
2013
27
Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report. ( 23722511 )
2013
28
Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. ( 23781249 )
2013
29
Large polyp of the small intestine: an unexpected metastasis of ovarian carcinosarcoma. ( 23926191 )
2013
30
Prognostic determinants in patients with uterine and ovarian carcinosarcoma. ( 23947079 )
2013
31
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. ( 22209775 )
2012
32
Complete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of assessment of the response by FDG-PET. ( 24371621 )
2012
33
Malignant melanoma arising in an ovarian carcinosarcoma: case report and review of the literature. ( 21293284 )
2011
34
Solitary splenic metastasis from ovarian carcinosarcoma: a case report. ( 21310035 )
2011
35
A rare case of ovarian carcinosarcoma successfully treated with the neoadjuvant chemotherapy of paclitaxel and ifosfamide. ( 21417665 )
2011
36
Whole-body FDG PET/CT in diagnosis of internal mammary nodal metastasis of ovarian carcinosarcoma. ( 21552025 )
2011
37
Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. ( 19820383 )
2009
38
Current management of ovarian carcinosarcoma. ( 17362309 )
2007
39
Clinical features and outcomes of uterine and ovarian carcinosarcoma. ( 16271748 )
2006
40
Complete cytoreduction combined with early postoperative intraperitoneal chemotherapy for ovarian carcinosarcoma. Report of two cases. ( 16645301 )
2006
41
A case of primary ovarian carcinosarcoma and vulvar carcinoma with widespread lymphadenopathy. ( 16846899 )
2006
42
Primary ovarian carcinosarcoma: a case report and review of the literature. ( 15493190 )
2004
43
Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. ( 12893202 )
2003
44
Unusual Trousseau's syndrome in ovarian carcinosarcoma: multiple systemic thromboembolic events. ( 12554280 )
2002
45
Borderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma. ( 12574850 )
2001
46
Ovarian carcinosarcoma [correction of carcinoma]. ( 11418412 )
2001
47
Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. ( 11119124 )
2000
48
MR images of ovarian carcinosarcoma. ( 10646984 )
1999

Variations for Ovarian Carcinosarcoma

Expression for Ovarian Carcinosarcoma

Search GEO for disease gene expression data for Ovarian Carcinosarcoma.

Pathways for Ovarian Carcinosarcoma

GO Terms for Ovarian Carcinosarcoma

Sources for Ovarian Carcinosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....